Figure 1. Responses to treatment before haploidentical-BMT. Shown are PET-CT images performed after each respective treatment (Post-Rx). Post-Dx mo. indicate months after initial diagnosis. (A) extension of disease below the diaphragm following dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) and involved field irradiation; (B) interim response after receiving ifosfamide, carboplatin, etoposide and rituximab (ICE-R), then navelbine and doxorubicin (R-GND) followed by first dose of pembrolizumab; (C) progression of disease after eight doses of pembrolizumab; (D) partial response after brentuximab vedotin; (E) failure to respond to anti-CD19 CAR-T cell therapy; (F) very good partial response after bendamustine and brentuximab followed by gemcitabine, cisplatin and dexamethasone (GCD).